The pharmaceutical giant, Eli Lilly has just launched its newly approved GLP-1 product, Zepbound, in a direct-to-consumer approach on its Lilly Direct
The medication comes from licensed 503A compounding pharmacies, is available in all 50 states without insurance, and qualifies for HSA/FSA accounts
The campaign emphasized that although the monetary cost of compounded versions may be lower, the true cost could be patient safety
Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters
Proactive dual therapy makes more sense than reactive addition after muscle loss has already occurred
If using injectable B12, inject at a different site than your GLP-1 shot